Atrial fibrillation is the most common sustained arrhythmia seen in clinical practice. In the Framingham study, the incidence is estimated to be 2% to 4% of the general population above 65 years of age [1]. The incidence is even higher in patients with underlying heart disease [2]. Atrial fibrillation may be associated with hemodynamic impairment, occasionally disabling symptoms, and a decrease in life expectancy. In advanced heart failure, atrial fibrillation is common and was found to be a marker for increased risk of death [3]. The most important concern with atrial fibrillation relates to its embolic manifestations that, in 75% of instances, result in cerebrovascular accidents [4, 5].